February 10, 2004

Extramural Update February 2004

Introduction Whereas most studies focus on laboratory and clinical research, little is known about the causes of death and risk factors for death in critically ill patients. Methods Three thousand seven hundred patients admitted to an adult intensive care unit (ICU) were prospectively evaluated. Study endpoints were to evaluate causes of death and risk factors for death in the ICU, in the hospi...

Thursday 26 February 2004

s of the 2nd Scientific Conference "Restauración Neurológica 2004" 252 Centro Internacional de Restauración Neurológica, Ciudad de la Habana, Cuba. Instituto Cajal, CSIC, Madrid, Spain Treatment with L-DOPA is today the most efficacious, non-invasive therapy for Parkinson’s Disease. However, chronic treatment with L-DOPA induces in most of the patients the appearance of abnormal involuntary mov...

Fellowships Grants and Awards February 2004

The complex biology of critical illness not only reflects the initial insult that brought the patient to the intensive care unit but also, and perhaps even more importantly, it reflects the consequences of the many clinical interventions initiated to support life during a time of lethal organ system insufficiency. The latter may amplify or modify the response to the former and are eminently ame...

Cover vol. 10, no. 1, February 2013

Book Review | New Books February 2004

Polymyxin B and polymyxin E (colistin) are the two polymyxins used in clinical practice. Colistin is a polymyxin-type antibiotic, disrupting the structure of Gram-negative organisms’ cell membranes, rarely used parenterally because it has nephrotoxic side effects. The polymyxins are active against selected Gram-negative bacteria, including Acinetobacter species, Pseudomonas aeruginosa, Klebsiel...